The role of membrane fusion activity of a whole inactivated influenza virus vaccine in (re)activation of influenza-specific cytotoxic T lymphocytes

Vaccine

Volumn 28, Issue 52, 2010, Pages 8280-8287

  Budimir, Natalija ^a   Meijerhof, Tjarko ^a   Wilschut, Jan ^a   Huckriede, Anke ^a   de Haan, Aalzen ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cross presentation; Cross protection; CTL vaccine; Influenza; Whole inactivated virus

Indexed keywords

INFLUENZA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; CD8+ T LYMPHOCYTE; CELL STIMULATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG MECHANISM; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; MEMBRANE FUSION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGEN PRESENTATION; CROSS-PRIMING; DENDRITIC CELLS; FEMALE; INFLUENZA VACCINES; MEMBRANE FUSION; MICE; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE; RNA-BINDING PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, INACTIVATED; VIRAL CORE PROTEINS;

EID: 78649753669     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.10.007     Document Type: Article

References (45)

1. Fiore A.E., Bridges C.B., Cox N.J. Seasonal influenza vaccines. Curr Top Microbiol Immunol 2009, 333:43-82.
2. Clements M.L., Betts R.F., Tierney E.L., Murphy B.R. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 1986, 24(1):157-160.
3. Gerhard W. The role of the antibody response in influenza virus infection. Curr Top Microbiol Immunol 2001, 260:171-190.
4. de Jong J.C., Beyer W.E., Palache A.M., Rimmelzwaan G.F., Osterhaus A.D. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 2000, 61(1):94-99.
5. Ping J., Li C., Deng G., Jiang Y., Tian G., Zhang S., et al. Single-amino-acid mutation in the HA alters the recognition of H9N2 influenza virus by a monoclonal antibody. Biochem Biophys Res Commun 2008, 371(1):168-171.
6. Fauci A.S. Pandemic influenza threat and preparedness. Emerg Infect Dis 2006, 12(1):73-77.
7. Brown L.E., Kelso A. Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes. Immunol Cell Biol 2009, 87(4):300-308.
8. Zweerink H.J., Askonas B.A., Milican D., Courtneidge S.A., Skehel J.J. Cytotoxic T cells to type A influenza virus; viral hemagglutinin induces A-strain specificity while infected cells confer cross-reactive cytotoxicity. Eur J Immunol 1977, 7(9):630-635.
9. Yewdell J.W., Bennink J.R., Smith G.L., Moss B. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 1985, 82(6):1785-1789.
10. Lee L.Y., Ha do L.A., Simmons C., de Jong M.D., Chau N.V., Schumacher R., et al. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 2008, 118(10):3478-3490.
11. Kreijtz J.H.C.M., de Mutsert G., van Baalen C.A., Fouchier R.A.M., Osterhaus A.D.M.E., Rimmelzwaan G.F. Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J Virol 2008, 82(11):5161-5166.
12. Topham D.J., Tripp R.A., Doherty P.C. CD8+ T cells clear influenza virus by perforin or Fas-dependent processes. J Immunol 1997, 159(11):5197-5200.
13. Bender B.S., Croghan T., Zhang L., Small P.A. Transgenic mice lacking class I major histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge. J Exp Med 1992, 175(4):1143-1145.
14. York I.A., Rock K.L. Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol 1996, 14:369-396.
15. Storni T., Lechner F., Erdmann I., Bachi T., Jegerlehner A., Dumrese T., et al. Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles. J Immunol 2002, 168(6):2880-2886.
16. Larsson M., Messmer D., Somersan S., Fonteneau J.F., Donahoe S.M., Lee M., et al. Requirement of mature dendritic cells for efficient activation of influenza A-specific memory CD8+ T cells. J Immunol 2000, 165(3):1182-1190.
17. Brossart P., Bevan M.J. Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines. Blood 1997, 90(4):1594-1599.
18. Amigorena S., Savina A. Intracellular mechanisms of antigen cross presentation in dendritic cells. Curr Opin Immunol 2010, 22(1):109-117.
19. Ramachandra L., Simmons D., Harding C.V. MHC molecules and microbial antigen processing in phagosomes. Curr Opin Immunol 2009, 21(1):98-104.
20. Gromme M., Neefjes J. Antigen degradation or presentation by MHC class I molecules via classical and non-classical pathways. Mol Immunol 2002, 39(3-4):181-202.
21. Ackerman A.L., Cresswell P. Cellular mechanisms governing cross-presentation of exogenous antigens. Nat Immunol 2004, 5(7):678-684.
22. Fretz M.M., Mastrobattista E., Koning G.A., Jiskoot W., Storm G. Strategies for cytosolic delivery of liposomal macromolecules. Int J Pharm 2005, 298(2):305-309.
23. Vasir J.K., Labhasetwar V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv Drug Deliv Rev 2007, 59(8):718-728.
24. Shen H., Ackerman A.L., Cody V., Giodini A., Hinson E.R., Cresswell P., et al. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology 2006, 117(1):78-88.
25. Huckriede A., Bungener L., Stegmann T., Daemen T., Medema J., Palache A.M., et al. The virosome concept for influenza vaccines. Vaccine 2005, 23(Suppl. 1):S26-38.
26. Skehel J.J., Bayley P.M., Brown E.B., Martin S.R., Waterfield M.D., White J.M. Changes in the conformation of influenza virus hemagglutinin at the pH optimum of virus-mediated membrane fusion. Proc Natl Acad Sci U S A 1982, 79(4):968-972.
27. Burgdorf S., Scholz C., Kautz A., Tampe R., Kurts C. Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat Immunol 2008, 9(5):558-566.
28. Kurts C., Robinson B.W., Knolle P.A. Cross-priming in health and disease. Nat Rev Immunol 2010, 10(6):403-414.
29. Di Pucchio T., Chatterjee B., Smed-Sorensen A., Clayton S., Palazzo A., Montes M., et al. Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I. Nat Immunol 2008, 9(5):551-557.
30. Datta S.K., Redecke V., Prillman K.R., Takabayashi K., Corr M., Tallant T., et al. A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J Immunol 2003, 170(8):4102-4110.
31. Suzuki Y., Wakita D., Chamoto K., Narita Y., Tsuji T., Takeshima T., et al. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity. Cancer Res 2004, 64(23):8754-8760.
32. Geeraedts F., Goutagny N., Hornung V., Severa M., de Haan A., Pool J., et al. Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog 2008, 4(8):e1000138.
33. Geeraedts F., Saluja V., ter Veer W., Amorij J.P., Frijlink H.W., Wilschut J., et al. Preservation of the immunogenicity of dry-powder influenza H5N1 whole inactivated virus vaccine at elevated storage temperatures. AAPS J 2010, 12(2):215-222.
34. Peterson G.L. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem 1977, 83(2):346-356.
35. Stegmann T., Morselt H.W., Booy F.P., van Breemen J.F., Scherphof G., Wilschut J. Functional reconstitution of influenza virus envelopes. EMBO J 1987, 6(9):2651-2659.
36. Stambas J., Doherty P.C., Turner S.J. An in vivo cytotoxicity threshold for influenza A virus-specific effector and memory CD8(+) T cells. J Immunol 2007, 178(3):1285-1292.
37. Veiga-Fernandes H., Walter U., Bourgeois C., McLean A., Rocha B. Response of naive and memory CD8+ T cells to antigen stimulation in vivo. Nat Immunol 2000, 1(1):47-53.
38. Curtsinger J.M., Lins D.C., Mescher M.F. CD8+ memory T cells (CD44high, Ly-6C+) are more sensitive than naive cells to (CD44low, Ly-6C-) to TCR/CD8 signaling in response to antigen. J Immunol 1998, 160(7):3236-3243.
39. Pihlgren M., Dubois P.M., Tomkowiak M., Sjogren T., Marvel J. Resting memory CD8+ T cells are hyperreactive to antigenic challenge in vitro. J Exp Med 1996, 184(6):2141-2151.
40. Houde M., Bertholet S., Gagnon E., Brunet S., Goyette G., Laplante A., et al. Phagosomes are competent organelles for antigen cross-presentation. Nature 2003, 425(6956):402-406.
41. Rodriguez A., Regnault A., Kleijmeer M., Ricciardi-Castagnoli P., Amigorena S. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1999, 1(6):362-368.
42. Yewdell J.W. Designing CD8+ T cell vaccines: it's not rocket science (yet). Curr Opin Immunol 2010, 22(3):402-410.
43. Diebold S.S., Kaisho T., Hemmi H., Akira S., Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004, 303(5663):1529-1531.
44. Furuya Y., Regner M., Lobigs M., Koskinen A., Mullbacher A., Alsharifi M. Effect of inactivation method on the cross-protective immunity induced by whole 'killed' influenza A viruses and commercial vaccine preparations. J Gen Virol 2010, 91(Pt. 6):1450-1460.
45. Bodewes R., Kreijtz J.H.C.M., Hillaire M.L.B., Geelhoed-Mieras M.M., Fouchier R.A.M., Osterhaus A.D.M.E., et al. Vaccination with whole inactivated virus vaccine affects the induction of heterosubtypic immunity against influenza virus A/H5N1 and immunodominance of virus-specific CD8+ T-cell responses in mice. J Gen Virol 2010, 91(Pt. 7):1743-1753.